Differential expression of sema3A and sema7A in a murine model of multiple sclerosis Implications for a therapeutic design

Differential expression of sema3A and sema7A in a murine model of multiple sclerosis : Implications for a therapeutic design

We characterised the expression of semaphorin (sema)3A, sema7A and their receptors in the immune and the central nervous system (CNS) at different stages of experimental autoimmune encephalomyelitis (EAE). We also studied their expression in neonatal and adult oligodendrocyte progenitor cell (OPC) a...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 163(2016) vom: 21. Feb., Seite 22-33
1. Verfasser: Gutiérrez-Franco, Ana (VerfasserIn)
Weitere Verfasser: Costa, Carme, Eixarch, Herena, Castillo, Mireia, Medina-Rodríguez, Eva M, Bribián, Ana, de Castro, Fernando, Montalban, Xavier, Espejo, Carmen
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2016
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Experimental autoimmune encephalomyelitis Immune response Multiple sclerosis Neurodegeneration Semaphorin Antigens, CD Sema3a protein, mouse Sema7a protein, mouse mehr... Semaphorin-3A Semaphorins
Beschreibung
Zusammenfassung:We characterised the expression of semaphorin (sema)3A, sema7A and their receptors in the immune and the central nervous system (CNS) at different stages of experimental autoimmune encephalomyelitis (EAE). We also studied their expression in neonatal and adult oligodendrocyte progenitor cell (OPC) and in mature oligodendrocyte cultures. Our results show that sema3A is increased in the CNS and decreased in the immune system upon EAE induction. However, sema7A expression is increased in both the CNS and the immune system during EAE. We also detected sema3A, sema7A and their receptors in neonatal and adult OPCs and in mature oligodendrocytes. These data suggest that sema3A and sema7A are involved in the pathogenesis of EAE, in the modulation of the immune response and in the neurodegeneration that take place in the CNS. Sema7A may represent an intriguing potential therapeutic target for the treatment of both the neurodegenerative and immune-mediated disease processes in MS
Beschreibung:Date Completed 28.06.2016
Date Revised 09.04.2022
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2015.12.005